Does Biotech Consulting Revenue Qualify for Pipe or Capchase?

No. Grant-funded engagements are tied to a funding body's disbursement schedule, which your client doesn't fully control and which can pause or restructure with little notice. Neither Pipe nor Capchase can underwrite a payment source that depends on a third party's grant cycle, even when the underlying client relationship is long-standing and reliable.

This is true even for multi-year grant-funded programs with a strong track record of renewal. Renewal history helps your credibility with a client, but it doesn't create the calendar-based, contractually recurring payment pattern either platform requires.

A flat monthly or quarterly retainer for ongoing regulatory monitoring, separate from any specific project, is structured closer to a subscription: defined scope, consistent fee, renewing term. If your firm has arrangements like this with pharmaceutical or medical device clients, that revenue line is what either provider would actually look at.

Even then, expect the advance to be sized to that retainer revenue specifically, not to your firm's total project-based billings, which for most life sciences consultancies will still be the larger share of the business.

A clinical trial design engagement billed across study milestones, protocol development, IRB submission, interim analysis, looks similar on paper to phase-based billing in engineering or architecture: real money, real predictability from your side, but no recurring collection pattern a lender can verify against a calendar. The engagement ends when the study phase concludes.

Don't present a long-running, multi-phase engagement as recurring revenue to try to qualify for a larger advance. Underwriters distinguish between a long project and a renewing subscription, and the two aren't interchangeable no matter how reliable the client relationship has been.

Structuring a project engagement as a series of short-term "renewing" contracts purely to create the appearance of recurring revenue is a bad idea for two reasons: it will likely be caught during underwriting when a provider reviews the actual scope and deliverables behind each renewal, and it complicates your own revenue recognition and client contracting for no real benefit if financing falls through anyway.

If your recurring regulatory retainer book is thin, it's more useful to build that line honestly over time, converting a few of your most consistent clients to a standing advisory arrangement, than to misrepresent project work to a lender.

Say your firm has a signed monthly regulatory monitoring retainer with a mid-sized device manufacturer, alongside a larger, grant-funded clinical consulting engagement whose next disbursement is delayed while the funding agency processes paperwork. The retainer keeps paying regardless of the grant delay, so advancing part of its value through Pipe could bridge payroll for the weeks the grant payment is stuck in process.

This only works because the retainer itself is stable and unrelated to the delayed grant. If the same client relationship funded both the retainer and the grant-backed project, and something at the client itself, not the funding agency, were causing the delay, financing against that retainer would be financing risk you're already exposed to twice over. Check that the recurring revenue you're advancing is genuinely independent of whatever cash gap you're trying to bridge.

For a life sciences consultancy that is mostly grant-funded and milestone project work, a traditional bank line of credit sized against the firm's general financial position is usually the more realistic option, since it doesn't require subscription-shaped revenue. Whatever rate you're quoted there or through Pipe or Capchase will still be priced off the same base: the effective federal funds rate at 3.63 percent¹ and the bank prime loan rate at 6.75 percent².

Building a cash reserve during well-funded grant periods to cover gaps during slower funding cycles is also worth considering as a first line of defense, since it avoids financing costs entirely for a revenue pattern that neither platform is well suited to address.

If your revenue is mostly grants and milestones, weigh these options:

• A traditional bank line of credit sized against the firm's general financial position, which doesn't require recurring revenue.
• Specialty bridge financing against confirmed but undisbursed grant awards, which some lenders offer.
• Selling standing regulatory affairs monitoring retainers, since that is the revenue line either provider can actually evaluate.
• Waiting until the retainer line is a meaningful, growing part of the practice before pursuing revenue-based financing.